Daily Sepsis Research Analysis
Analyzed 24 papers and selected 3 impactful papers.
Summary
Three papers advance sepsis science and practice: (1) a mechanistic discovery that mrkH inactivation drives autoaggregation-mediated carbapenem tolerance in Klebsiella pneumoniae bloodstream isolates; (2) plasma metabolomic signatures that accurately identify multidrug-resistant sepsis at admission; and (3) a meta-analysis showing no mortality or ICU stay benefit of levosimendan versus dobutamine in septic cardiomyopathy.
Research Themes
- Antimicrobial resistance and rapid diagnostics
- Mechanisms of antibiotic tolerance and bacterial multicellular behavior
- Hemodynamic support choices in septic cardiomyopathy
Selected Articles
1. Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates.
In bloodstream isolates of Klebsiella pneumoniae species complex lacking carbapenemases, a frameshift in mrkH drove autoaggregation, conferring carbapenem tolerance without increased MIC. Genetic complementation reversed tolerance, and physically disrupting aggregates reduced survival, establishing autoaggregation as a protective tolerance mechanism.
Impact: Revealing mrkH-linked autoaggregation as a tolerance mechanism challenges MIC-centric susceptibility assessment and highlights multicellular behaviors as therapeutic targets against Gram-negative sepsis.
Clinical Implications: Tolerance via aggregation can blunt bactericidal activity despite susceptible MICs, suggesting the need to assess tolerance phenotypes, consider agents/strategies that disrupt aggregation or enhance killing, and avoid relying solely on MIC for K. pneumoniae bacteremia.
Key Findings
- Among 50 bloodstream isolates, three showed carbapenem tolerance without carbapenemases; two carried blaDHA-1 with reduced meropenem activity.
- An mrkH frameshift decreased mrkA expression and enhanced autoaggregation, sustaining survival under meropenem exposure.
- Wild-type mrkH complementation reduced tolerance; disrupting aggregates markedly decreased survival, implicating aggregation in physical protection.
Methodological Strengths
- Integrated genomics (WGS), time-kill kinetics, genetic complementation, and phenotypic assays for triangulation.
- Use of clinical bloodstream isolates increases translational relevance.
Limitations
- Small number of tolerant isolates analyzed and absence of in vivo validation.
- No direct linkage to patient outcomes or pharmacodynamic optimization strategies.
Future Directions: Quantify clinical prevalence of mrkH-linked tolerance, evaluate anti-aggregation adjuvants in vivo, and develop clinical testing for tolerance phenotypes alongside MIC.
OBJECTIVE: The objective of this study is to elucidate the phenotypic and genetic basis of carbapenem tolerance in Klebsiella pneumoniae species complex bloodstream isolates lacking carbapenemase genes, with a focus on multicellular behaviours.
MATERIALS AND METHODS: Fifty clinical K. pneumoniae species complex isolates from bloodstream infections were screened for reduced susceptibility to meropenem. Five strains (MIC 1-2 mg/L) lacking carbapenemase genes were analysed using whole-genome sequencing, time-kill assays, plasmid-based gene expression assays and phenotypic assays, including autoaggregation and biofilm formation.
RESULTS: The results of the time-kill assay showed that three strains were carbapenem tolerant. Two strains carrying blaDHA-1 exhibited reduced meropenem activity and enhanced survival following drug exposure. One isolate showed sustained survival and carried a frameshift mutation in mrkH, leading to downregulation of mrkA expression and enhanced autoaggregation. Complementation with wild-type mrkH reduced tolerance. Disruption of cellular aggregates significantly decreased survival, indicating that aggregation provides physical protection against meropenem.
CONCLUSIONS: This study identified mrkH-linked autoaggregation as a novel mechanism of carbapenem tolerance in Klebsiella isolates. Overall, the findings underscore the role of multicellular behaviours in antibiotic resilience and highlight the potential clinical relevance of non-carbapenemase-mediated tolerance mechanisms.
2. Plasma metabolomic signatures in patients with multidrug-resistant bacterial sepsis.
Two independent cohorts (n=198 each) revealed robust, distinct plasma metabolomic signatures for MDR gram-negative and gram-positive sepsis. An 8-metabolite model for MDR gram-negative infection achieved AUROC 0.878 in external validation, suggesting feasibility for rapid admission-time risk stratification to inform antimicrobial stewardship.
Impact: Demonstrates externally validated, admission-time metabolomic prediction of MDR sepsis, a step toward faster, stewardship-aligned therapy before culture results.
Clinical Implications: If translated into a rapid assay, metabolomic panels could guide early escalation or de-escalation aligned with MDR risk, reducing inappropriate broad-spectrum exposure and improving outcomes.
Key Findings
- Distinct plasma signatures differentiated MDR gram-negative (elevated histamine; decreased cholic and benzoic acids) from susceptible infections.
- MDR gram-positive sepsis showed altered energy/amino acid metabolism with elevated 2-hydroxyglutarate.
- An 8-metabolite model for MDR gram-negative achieved AUROC 0.885 (discovery) and 0.878 (validation); MDR gram-positive model showed AUROC 0.763/0.715.
Methodological Strengths
- Discovery and independent validation cohorts with LC-MS/MS quantification.
- Multiple machine learning approaches and external performance reporting (AUROC with CIs).
Limitations
- Observational design precludes causal inference and may be affected by unmeasured confounders.
- Clinical utility, turnaround time, and cost-effectiveness of a bedside assay remain untested.
Future Directions: Prospective implementation studies with clinical decision support to test impact on time-to-appropriate therapy, antimicrobial exposure, and outcomes across diverse settings.
BACKGROUND AND OBJECTIVE: Multidrug-resistant (MDR) bacterial infections are a leading cause of sepsis-related death. A rapid method to identify patients with MDR infections upon hospital admission is urgently needed. This study aimed to characterize the distinct plasma metabolomic signatures associated with MDR gram-positive (G+) and gram-negative (G-) sepsis and to develop predictive models for rapid, risk stratification during the initial clinical encounter.
METHODS: Two independent cohorts of septic patients were recruited, with 198 subjects (117 MDR and 81 susceptible) in the discovery cohort, and 198 patients (95 MDR and 103 susceptible) in the validation cohort. Plasma metabolomic profiling was performed using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Multiple machine learning algorithms were employed to identify differential metabolomic signatures and to construct and validate multi-metabolite models for the early identification of MDR bacteria.
RESULTS: Distinct metabolomic signatures were identified for both MDR G- and G+ infections. MDR G- sepsis showed significant elevations in metabolites related to host inflammatory responses, such as histamine, alongside decreased levels of gut microbiota-derived metabolites, including cholic acid and benzoic acid, indicating profound host-microbe dysregulation. Conversely, MDR G+ sepsis was characterized by alterations in energy and amino acid metabolism, notably elevated 2-hydroxyglutarate, a marker of mitochondrial stress. An 8-metabolite model for MDR G- infection achieved excellent discrimination in both the discovery (AUROC = 0.885, 95% CI: 0.787-0.982) and validation (AUROC = 0.878, 95% CI: 0.782-0.951) cohorts. The model for MDR G+ infection demonstrated good predictive performance (AUROC = 0.763 and 0.715 in discovery and validation, respectively).
CONCLUSION: This study identifies robust and distinct plasma metabolomic signatures that differentiate MDR from antibiotic-susceptible sepsis. These findings support the development of rapid, metabolomics-based testing using admission plasma to risk-stratify patients. This approach could guide early, stewardship-aligned antimicrobial decisions while conventional culture results are pending, potentially improving clinical outcomes.
3. Comparative efficacy of levosimendan and dobutamine in sepsis-related cardiac impairment: a meta-analysis.
Across 9 RCTs (n=289), levosimendan did not reduce mortality or ICU length of stay compared with dobutamine in septic cardiac dysfunction, and infection risks were similar. Findings argue against routine levosimendan preference and highlight the need for larger, targeted trials.
Impact: Synthesizes randomized evidence to guide inotrope choice in septic cardiomyopathy, discouraging routine levosimendan use absent subgroup benefit.
Clinical Implications: Do not preferentially choose levosimendan over dobutamine for septic cardiac dysfunction; base selection on patient profile, hemodynamics, availability, and cost until new evidence emerges.
Key Findings
- No mortality reduction with levosimendan versus dobutamine (OR 0.89, 95% CI 0.52–1.54; I²=0%).
- ICU length of stay showed no significant difference (MD −2.02 days; I²=83%).
- Hospital-acquired infections (pneumonia, peritonitis, UTI) were comparable between groups.
Methodological Strengths
- Inclusion limited to RCTs with predefined outcomes; PROSPERO-registered protocol.
- Heterogeneity-informed model selection (random vs fixed effects) with I² reporting.
Limitations
- Total sample size remains small and trials vary in dosing, timing, and patient selection.
- High heterogeneity for ICU length of stay limits precision; subgroup effects remain uncertain.
Future Directions: Conduct adequately powered, CONSORT-compliant RCTs to test levosimendan in phenotyped septic cardiomyopathy (e.g., low-output vasoplegia) with standardized dosing and patient-centered outcomes.
BACKGROUND: Sepsis-induced cardiac dysfunction significantly impacts patient outcomes, with inotropic support playing a crucial role in management. Levosimendan and dobutamine are commonly used, but their comparative efficacy remains debated. This meta-analysis evaluates the efficacy and safety of levosimendan versus dobutamine in sepsis-related cardiac impairment, focusing on mortality, intensive care unit (ICU) outcomes, and infection risks.
METHODS: We systematically analyzed randomized controlled trials (RCTs) comparing levosimendan and dobutamine in septic patients with cardiac dysfunction. Primary outcomes included mortality and ICU length of stay, while secondary outcomes assessed pneumonia, peritonitis, and urinary tract infection (UTI) risks. Model selection for pooled odds ratios (OR) or mean differences (MD) with 95% confidence intervals (CI) was based on heterogeneity, employing random-effects models for substantial heterogeneity (I² > 50%) and fixed-effects models otherwise. Meta-analyses were performed using Rev-Man 5.4.
STUDY REGISTRATION: Prospero ID (CRD420261283881).
RESULTS: The meta-analysis included 9 RCTs (n = 289 patients) in total. For mortality, data were available from 8 RCTs (n = 239 patients), revealing no significant reduction with levosimendan compared to dobutamine (OR: 0.89, 95% CI: 0.52-1.54, P = 0.68; I²=0%). For ICU length of stay, 7 RCTs (n = 241 patients) were included, showing no significant difference (MD - 2.02 days, 95% CI - 6.44 to 2.39; P = 0.37; I²=83%). Regarding hospital-acquired infections, pneumonia was analyzed in 5 RCTs (n = 143 patients) (OR: 1.05, 95% CI: 0.48-2.29, P = 0.90; I²=0%), peritonitis in 3 RCTs (n = 98 patients) (OR 1.56, 95% CI 0.62-3.95; P = 0.35; I²=0%), and urinary tract infections in 3 RCTs (n = 91 patients) (OR: 0.70, 95% CI: 0.17-2.81, P = 0.61; I²=0%).
CONCLUSION: Current evidence indicates that levosimendan does not reduce mortality or ICU length of stay compared to dobutamine in sepsis-induced cardiac dysfunction, and infection risks are comparable. The high heterogeneity in ICU outcomes warrants cautious interpretation. These findings do not support the routine preferential use of levosimendan over dobutamine. Larger, well-designed trials are needed to identify specific patient subgroups that may benefit from levosimendan.